Bicycle Therapeutics plc

NasdaqGS:BCYC Stock Report

Market Cap: US$977.8m

Bicycle Therapeutics Management

Management criteria checks 2/4

Bicycle Therapeutics' CEO is Kevin Lee, appointed in Sep 2015, has a tenure of 8.58 years. total yearly compensation is $8.63M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $5.71M. The average tenure of the management team and the board of directors is 2.3 years and 4.8 years respectively.

Key information

Kevin Lee

Chief executive officer

US$8.6m

Total compensation

CEO salary percentage7.8%
CEO tenure8.6yrs
CEO ownership0.6%
Management average tenure2.3yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Bicycle Therapeutics EPS misses by $0.05, beats on revenue

May 06

Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Mar 08
Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Feb 23
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

Jan 19
Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

Bicycle Therapeutics gives out pipeline update, shares rise

Jan 14

What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Dec 15
What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Bicycle Therapeutics settles IP dispute with Pepscan

Nov 30

CEO Compensation Analysis

How has Kevin Lee's remuneration changed compared to Bicycle Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$181m

Sep 30 2023n/an/a

-US$162m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$9mUS$673k

-US$113m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$677k

-US$67m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$62m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$592k

-US$51m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$4mUS$517k

-US$31m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$818kUS$386k

-US$22m

Compensation vs Market: Kevin's total compensation ($USD8.63M) is above average for companies of similar size in the US market ($USD3.29M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.


CEO

Kevin Lee (55 yo)

8.6yrs

Tenure

US$8,627,590

Compensation

Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director8.6yrsUS$8.63m0.58%
$ 5.7m
Lee Kalowski
Presidentno dataUS$3.07m0.0059%
$ 57.3k
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$728.77k0.38%
$ 3.8m
Alistair Milnes
Chief Operating Officer2.3yrsUS$5.98m0.034%
$ 336.4k
Michael Skynner
Chief Technology Officer2.3yrsUS$3.07m0.11%
$ 1.1m
Christian Heinis
Scientific Founderno datano datano data
Alethia Young
Chief Financial Officerless than a yearno datano data
Travis Thompson
Senior VPless than a yearno data0.0043%
$ 41.8k
Nicholas Keen
Chief Scientific Officer7.3yrsno data0.054%
$ 532.9k
Zafar Qadir
General Counsel4yrsno datano data
David Borah
Senior Vice President of Capital Markets & Corporate Communicationsno datano datano data
Gillian Langford
Head of Clinical and Project Management7.9yrsno datano data

2.3yrs

Average Tenure

53yo

Average Age

Experienced Management: BCYC's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Lee
CEO & Executive Director8.6yrsUS$8.63m0.58%
$ 5.7m
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$728.77k0.38%
$ 3.8m
Keith Peters
Chairman of Scientific Advisory Board5.9yrsno datano data
Pierre Legault
Non-Executive Chairman5.1yrsUS$1.56m0%
$ 0
Veronica Geraldine Jordan
Independent Non-Executive Director4.5yrsUS$741.27k0%
$ 0
Richard Kender
Independent Non-Executive Director4.8yrsUS$775.27k0.025%
$ 246.8k
Garret FitzGerald
Member of Scientific Advisory Board3.5yrsno datano data
Caetano Reis e Sousa
Member of Scientific Advisory Board3.5yrsno datano data
Janice Bourque
Independent Non-Executive Director4.8yrsUS$743.77k0.025%
$ 246.8k
Geoffrey Shapiro
Member of Scientific Advisory Board5.9yrsno datano data
Charles Swanton
Member of Scientific Advisory Board3.5yrsno datano data
Jane Grogan
Member of Scientific Advisory Board3.5yrsno datano data

4.8yrs

Average Tenure

67yo

Average Age

Experienced Board: BCYC's board of directors are considered experienced (4.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.